What is the optimal duration of neoadjuvant chemoimmunotherapy for resectable non-small cell lung cancer (NSCLC)?: a real-world study
European Journal of Cardio-Thoracic Surgery · 2025
DOI: 10.1093/ejcts/ezaf218 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cardio-Thoracic Surgery, 2025. Verfasst von Zhoujunyi Tian und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, China-Japan Friendship Hospital, Beijing 100029, P. R. China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Neoadjuvant Therapy, Lung Neoplasms, Immunotherapy. Die Arbeit nennt 24 Literaturangaben. Gefördert von: National High Level Hospital Clinical Research Funding.
Abstract (Originalsprache)
Objectives
The optimal duration of neoadjuvant chemoimmunotherapy for resectable non-small cell lung cancer remains unknown. This study aimed to assess whether the number of cycles of neoadjuvant therapy affects oncologic efficacy and surgical safety in a real-world setting.
Methods
Patients with resectable non-small cell lung cancer who received neoadjuvant chemoimmunotherapy and subsequent surgery were included. Patients were divided into 2 groups: ≤2 or >2 cycles. Oncology outcomes such as pathological complete response (pCR) and surgical outcomes were compared. Binary logistic regression analyses were conducted to identify independent factors for pCR. Kaplan-Meier analysis was used to compare long-term survival between groups. Cox regression analyses were conducted to identify independent predictors of recurrence.
Results
A total of 140 patients with clinical stage IB-IIIB disease were included; 68 received ≤2 cycles and 72 received >2 cycles of neoadjuvant chemoimmunotherapy. No significant differences between groups were observed in pCR rates, surgery difficulty, and postoperative complications. Multivariate binary logistic regression analysis indicated that adenocarcinoma [odds ratio 0.14, 95% confidence interval 0.04-0.50, P = .003] and clinical T3 stage (odds ratio 0.18, 95% confidence interval 0.05-0.72, P = .015) were unfavourable factors for pCR. Kaplan-Meier survival analysis revealed no significant difference in recurrence-free survival or overall survival between groups. Multivariate Cox regression analysis revealed that the number of neoadjuvant cycles was not a predictor of recurrence (hazard ratio 0.87, 95% confidence interval 0.31-2.44, P = .8).
Conclusions
Compared with 3 or more cycles, 2 cycles of neoadjuvant chemoimmunotherapy might achieve similar perioperative outcomes and long-term survival in selected patients. Prospective studies and extended follow-up are needed to verify the conclusions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, China-Japan Friendship Hospital, Beijing 100029, P. R. China.
Förderung
- National High Level Hospital Clinical Research Funding
Zitieren
APA
Tian, Z., Yang, H., Zhang, J., Liu, D., Liang, C., & Zhang, Z. (2025). What is the optimal duration of neoadjuvant chemoimmunotherapy for resectable non-small cell lung cancer (NSCLC)?: a real-world study. European Journal of Cardio-Thoracic Surgery. https://doi.org/10.1093/ejcts/ezaf218
Vancouver
Tian Z, Yang H, Zhang J, Liu D, Liang C, Zhang Z. What is the optimal duration of neoadjuvant chemoimmunotherapy for resectable non-small cell lung cancer (NSCLC)?: a real-world study. European Journal of Cardio-Thoracic Surgery. 2025. doi:10.1093/ejcts/ezaf218
BibTeX
@article{Tian2025,
author = {Tian, Zhoujunyi and Yang, Haoshuai and Zhang, Jin and Liu, Deruo and Liang, Chaoyang and Zhang, Zhenrong},
title = {What is the optimal duration of neoadjuvant chemoimmunotherapy for resectable non-small cell lung cancer (NSCLC)?: a real-world study},
journal = {European Journal of Cardio-Thoracic Surgery},
year = {2025},
doi = {10.1093/ejcts/ezaf218}
}
EUVIMED